Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
... 1 study and demonstrated declines in circulating tumor
cells and evidence of reduction in tumor
Eli Lilly and Company recently ... data confirming that LY2181308 penetrates tumor
tissue and reduces survivin mRNA and protein ...
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
... the bone complications, or SREs, caused by the tumor
are reduced or delayed. The primary and secondary ... needs. Amgen is studying denosumab in numerous tumor
types across the spectrum of cancer induced bone ... patients and as high as 75 percent in solid tumor
With bone metastases the growing ...
OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
... and its associated toxicities. Blood vessels in tumor
tissue, unlike blood vessels in normal tissue, ... to their leaky blood vessels and trapped in the tumor
bed allowing significantly more of the dose of chemotherapy to localize in the tumor
than with standard paclitaxel. Once inside ...
Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy
... from Self-Renewing, Proliferating Autologous tumor
Cells as Patient-Specific Anti-Tumor Vaccines in ... the patient's immune system to react against tumor
stem cells or early progenitor cells that can ... observed following vaccination with irradiated tumor
cells in 48 melanoma patients in a previous trial ...
National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness
... preclinical studies to provide clues into tumor
susceptibility mechanisms for brostallicin, a ... trabectedin, the NCI research indicates that the tumor
cell DNA damaging effects of brostallicin are enhanced by high tumor
glutathione levels, a hallmark of drug-resistant ...
Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
... with Eric Holland, MD, PhD, Director of the Brain tumor
group at Memorial Sloan-Kettering Cancer Center, ... that single agent perifosine not only induced tumor
regression and delayed tumor
growth, but that perifosine also improved the ...
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
... the bone complications, or SREs, caused by the tumor
are reduced or delayed. The primary and ... needs. Amgen is studying denosumab in numerous tumor
types across the spectrum of cancer induced bone ... the bone around the tumor. The damage the tumor
has caused to the bone can result in a number of ...
Alfacell Provides Shareholder Update
... can be widely used in therapy of different tumor
types, including most common types such as cancer ... Onconase to Cisplatin significantly increased the tumor
growth inhibition compared to Cisplatin or Onconase alone, and in the tumor
model most resistant to platinum, Onconase ...
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
... - Afinitor significantly reduced tumor
size by 50% or more in one out of three patients ... experienced a 50% or greater reduction in tumor
size. This 33% overall response rate (ORR) is defined as complete or partial tumor
shrinkage (95% confidence interval: 26-41%). The ...
Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
... CEO. "Thiarabine has been in two Phase 1/2 solid tumor
trials and was shown to have significant ... and their combinations were tested in five tumor
models. "In all cases, thiarabine demonstrated superior tumor
growth inhibition than clofarabine when the ...
Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
... - 71% Objective tumor
Response in Combination with Docetaxel in Advanced Breast Cancer -
- 65% Objective tumor
Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer -
- 64% Objective tumor
Response in Combination with ...
Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
... by a factor of 1.5 to 2.0, OPAXIO increases tumor
specific radiation cell kill by a factor of 7.2 ... conjugate is a potent enhancer of tumor
radiocurability , Int'l J. Radiat. Oncol. Biol. ... accumulation of paclitaxel poliglumex in tumor
tissue with continual slow release of the active ...
CuraGen Updates CR011-vcMMAE Data at ASCO
... disease. Fifty percent (50%) of patients showed tumor
shrinkage. Toxicities were similar to those ... progression-free survival (PFS) was 4.4 months. tumor
shrinkage was observed in 58% of patients, and 20 ... PFS. Additionally, in a subset of patients with tumor
biopsies, high levels ...
Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
... and from preclinical studies of XERECEPT in brain tumor
NTI sold the worldwide rights and ... with limited treatment options. The preclinical tumor
model studies indicate that XERECEPT(R) also has ... percent of these patients showing reductions in tumor
size of 50 percent or greater.
Celtic Pharma ...
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
... clinical benefit as determined by reductions in tumor
volume, reductions in tumor
markers, and improvement in cancer-related ... were demonstrated in patients with a variety of tumor
types including melanoma, renal cell, ovarian and ...
Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
... on clinical advances for its carfilzomib solid tumor
program in an oral presentation at the 2009 ... of the proteasome for treatment of solid tumor
patients. The compound's unique characteristics ... the Phase 1b/2 clinical trials of relapsed solid tumor
patients were presented by Dr. Rosen at the 2009 ...
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
... Phase I data on SF1126 in 36 advanced solid tumor
patients. The majority of patients were heavily ... disease for 20 weeks (5 mos.). These specific tumor
types are associated with aberrations of the PI3K ... outcomes.
Pharmacodynamic analysis of tumor
tissue confirmed inhibition of the PI3K pathway ...
Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
... inhibitor currently being studied in multiple tumor
types. These data were presented at the 45th ... Phase III clinical development program in various tumor
types for this new drug candidate."
... into a Phase III trial in one of the multiple tumor
types that may be responsive to BAY 73-4506."
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
... survival (PFS) and disease control measured by tumor
response rate. New data derived by three ... the safety and efficacy (assessed by objective tumor
response, PFS and overall survival) of ... expect those data later this year. The new PFS, tumor
response and neurotoxicity data provide the ...
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
... of treatment, Afinitor(R) stabilized or reduced tumor
size in 61% of patients with advanced liver ... These studies provide new research on multiple tumor
types and rare cancers.
To view the ... to placebo, more than doubled time without tumor
growth (15.6 months vs. 5.9 months) and reduced ...
Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
... that are expressed on the surface of new tumor
vasculature and within the tumor
In preclinical xenograft models ... is observed with high frequency in a variety of tumor
types. PI3K signaling through its downstream ...
BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
... prior to surgery. Patients who present with tumor
containing lymph nodes are particularly difficult ... by direct injection, at three dose levels, into tumor
containing lymph nodes in combination with ... low dose patient developed a new primary tumor
post treatment. OncoVEX GM-CSF was detected in ...
AlphaVax Announces Promising Results in Melanoma Studies
... vector particles (VRP) encoding melanoma-specific tumor
antigens to reduce melanoma tumor
burden in a state-of-the-art murine melanoma ... melanoma includes surgical removal of the tumor
tissue, followed by chemotherapy and/or radiation ...
Melanoma and Pregnancy: What Every Woman Needs to Know About the Risks, Prognosis
... for melanoma is based on three variables -- tumor
thickness, presence or absence of ulceration, and ... lymph nodes or other organs. For example, if a tumor
is less than 1 mm in depth (which is considered a ... of the disease), no ulceration is present in the tumor
(meaning the top layer of the skin when examined ...
Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
... patients in this cohort demonstrated an objective tumor
response according to RECIST criteria. These ... objectives of the study include measuring time to tumor
progression, duration of response, overall ... Patients in the study are evaluated regularly for tumor
response according to RECIST criteria. Patients ...
Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
... that in vitro, anti-PS antibodies
stimulate the tumor
microenvironment to recruit monocytes and other immune
cells to the tumor
with resulting anti-tumor effects, most likely ... the role of anti-PS
antibodies in mediating tumor
cell cytotoxicity and the tumor
New Body of Research Suggests Statin Use Benefits Multiple Areas of Urologic Health
... at radical prostatectomy, including adverse tumor
features and lower risk of positive surgical ... Association between statins, obesity and prostate tumor
inflammatory infiltrate in men undergoing radical ... tumor. Obesity may be associated with increased tumor
inflammation, and with more aggressive prostate ...
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
... patients with melanoma, a historically difficult tumor
to treat," said Todd Yancey, M.D., vice president ... Mechanism
Nexavar targets both the tumor
cell and tumor
vasculature. In preclinical studies, Nexavar has ...
Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model
... Mouse Equivalent to the Human Antibody Inhibited tumor
Growth in a Prostate Cancer Model by More than ... cells that line the blood vessels of tumors (the tumor
vascular endothelium), creating a specific target ... mobilize the body's immune system to destroy the tumor
Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
... are not active in colorectal cancer patients with tumor
cells harboring mutations in KRAS and BRAF ... 0.1 microgram/kilogram were sufficient to prevent tumor
growth from mutated human colorectal cancer ... a BiTE antibody against an undisclosed solid tumor
target. Additional BiTE antibodies, targeting ...
Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
... responses. In addition, MDX-1338 also reduced tumor
growth in acute myelogenous leukemia and lymphoma ... MDX-1110, an anti-Fucosyl-GM1 antibody in a SCLC tumor
model (Abstract #838)
Fucosyl-GM1 is a ... complement-dependent cytotoxicity) for killing tumor
cells. Additionally, MDX-1110 showed a favorable ...
First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
... (p<0.03 vs. baseline). In comparison, tumor
growth was observed across the saline control, ... cisplatinum arms. In addition, in the EP-100 arm tumor
volumes, weights and CA125 (a clinical biomarker ... treated tumors became necrotic, lacking viable tumor
cells after treatment. EP-100 was well tolerated ...
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
... Suppressing Effects of Tumors by Changing the tumor
Microenvironment and Mobilizing Key Components of ... selectively destroy the blood vessels supporting tumor
growth and spread and also to reverse the ability ... facilitate an important cytokine shift in the tumor
environment that subsequently encourages multiple ...
Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin
... to the genetic configuration in a patient's tumor
that makes it susceptible to a specific drug thus ... targeted therapies in preclinical experimental tumor
models. Brostallicin binds covalently to DNA ... interfering with DNA division and leading to tumor
cell death. More than 200 patients have been ...
New Imaging Analysis Predicts Brain Tumor Survival
... or MRI, protocol to monitor changes over time in tumor
blood volume within individual voxels of the ... researchers to see specific areas in which tumor
blood volume increased or decreased, that may ... and the relative cerebral blood flow of the tumor
to analyze voxel-wise changes among the serial ...
Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
... Carboplatin + Paclitaxel Achieved an Objective tumor
- Patient Dosing Initiated in ... cell lung cancer (NSCLC) achieved an objective tumor
response according to RECIST criteria, after ... very pleased to see these additional objective tumor
responses in this difficult-to-treat cancer ...
Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
... may turn on certain genes as a strategy by the tumor
to adapt to the therapy and become resistant to ... such as RAD51 as an adaptive strategy to help the tumor
repair the DNA damage done by these agents. In ... genes), effectively blocking the ability of the tumor
to repair its damaged DNA, sensitizing ...
Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
... - Afinitor more than doubled time without tumor
growth and reduced the risk of disease ... mTOR, a protein inside the cell that controls tumor
cell division and blood vessel growth
- ... with placebo, more than doubled the time without tumor
growth or death in patients with advanced kidney ...
Another LNA-based RNA Inhibitor Enters Clinical Trials
... EZN-3042 inhibited
Survivin expression and tumor
growth. It also potentiated the ... delivery of RNA antagonist
oligonucleotides in tumor
cells and in mice"
"EZN-2208, a novel ... specifically inhibits the growth of AR-positive tumor
"The antitumor activity of ...
MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
... study of liver stem cells and liver cancer.
tissues are composed of a mixture of cells with some tumor
cells exhibiting stem cell-like properties ... therapies that result in cytoreduction and thus tumor
regression, the control of cancer over a longer ...